Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
16 studies found for:    "Papilledema"
Show Display Options
RSS Create an RSS feed from your search for:
"Papilledema"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  aICP in Glaucoma and Papilledema
Conditions: Open-angle Glaucoma;   Papilledema
Intervention: Device: Non-invasive ICP measurement (Vittamed 305)
2 Not yet recruiting Ocular Point of Care Ultrasound (POCUS) to Detect Optic Disc Swelling in Comparison to Ophthalmologic Examination
Condition: Papilledema Associated With Increased Intracranial Pressure
Intervention: Device: Point of care ocular ultrasound
3 Recruiting Antiacne Medications Pseudotumor Cerebri
Condition: Optic Disc Swelling
Intervention: Other: Retinal nerve fibre layer measurement
4 Completed Assessment of Retinal Nerve Fibre Layer by Optical Coherence Tomography in Uveitis Patients With Papilloedema
Conditions: Uveitis;   Glaucoma
Intervention:
5 Terminated
Has Results
Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease
Conditions: Nervous System Malformations;   Arthropathy, Neurogenic;   Urticaria;   Papilledema
Intervention: Drug: anakinra
6 Not yet recruiting OCT Imaging of Papilledema in Pediatric Idiopathic Intracranial Hypertension
Condition: Pediatric Idiopathic Intracranial Hypertension
Intervention: Other: OCT Imaging
7 Recruiting Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery
Conditions: Cataract;   Retinal Edema;   Inflammation
Interventions: Drug: Prolensa (bromfenac 0.07%);   Drug: Ilevro (nepafenac 0.3%)
8 Available A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema
Condition: Diabetic Macular Edema
Intervention: Drug: Macugen (Pegaptanib Sodium)
9 Not yet recruiting Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF
Condition: Exudative Age Related Macular Degeneration
Intervention: Drug: Ranibizumab Injection [Lucentis]
10 Completed Ozurdex for Macular Edema Post Membrane Peeling
Conditions: Epiretinal Membrane;   Cellophane Maculopathy;   Macular Edema;   Retinal Edema
Interventions: Drug: Dexamethasone;   Drug: dexamethasone
11 Completed
Has Results
Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study
Condition: Diabetic Macular Edema
Intervention: Drug: Macugen® pegaptanib sodium
12 Completed Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting
Conditions: Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion;   Wet Age Related Macular Degeneration;   Diabetic Macular Edema;   Retinal Vein Occlusion
Interventions: Drug: Ranibizumab;   Other: Ranibizumab
13 Completed Idiopathic Intracranial Hypertension Treatment Trial
Condition: Idiopathic Intracranial Hypertension
Interventions: Drug: Acetazolamide;   Drug: Placebo;   Behavioral: Formal weight loss counselling program
14 Recruiting Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID / CAPS, DIRA, CANDLE, SAVI, CRMO, Still's Disease, Behcet's Disease, and Other Undifferentiated Autoinflammatory Diseases)
Conditions: Urticaria;   Arthropathy;   Lymphadenopathy;   Nervous System Anomalies
Intervention:
15 Active, not recruiting Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension.
Condition: Idiopathic Intracranial Hypertension
Interventions: Drug: AZD4017;   Other: Placebo
16 Withdrawn Disc Edema in Patients With Chronic Kidney Disease
Condition: Chronic Kidney Disease
Intervention:

Study has passed its completion date and status has not been verified in more than two years.